Mochida Pharmaceutical Co., Ltd. resolved to conduct a share buyback with an upper limit of 2,000,000,000 yen and 530,000 shares starting May 18, 2026, and to offer 1,153,600 shares through Mitsubishi UFJ Morgan Stanley Securities.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4534-20260330-02.pdf","jir_short_summary":"Mochida Pharmaceutical Co., Ltd. resolved to conduct a share buyback with an upper limit of 2,000,000,000 yen and 530,000 shares starting May 18, 2026, and to offer 1,153,600 shares through Mitsubishi UFJ Morgan Stanley Securities.","jir_summary":"### Overview of Share Offering and Share Buyback\nAt the board meeting on March 30, 2026, Mochida Pharmaceutical Co., Ltd. resolved to have the underwriting group, led by Mitsubishi UFJ Morgan Stanley Securities, purchase 1,153,600 ordinary shares through a share offering. The offering price will be determined based on the closing price on the Tokyo Stock Exchange during the period from April 6 to April 9, 2026. Additionally, there is a possibility of an additional share offering of up to 173,000 shares as an over-allotment, which will be priced in the same manner. Furthermore, it was also decided to implement a share buyback starting May 18, 2026, with upper limits of 2,000,000,000 yen and 530,000 shares.\n\n### Purpose of the Offering and Impact on Shareholders\nThis share offering aims to accelerate growth strategies and strengthen the stable profit base for the generic drug and biosimilar businesses according to the Mochida Pharmaceutical Group\u2019s medium-term management plan. In addition, in line with the reduction of policy holdings, it seeks to promote stock ownership among individual investors to enhance stock liquidity and gain long-term strategic understanding. The sellers are Taisho Pharmaceutical Holdings and Sumitomo Pharma, with a lock-up period set at 180 days from the share offering price determination date. This is expected to lead to changes in shareholder composition and improvements in capital efficiency.","jir_financial_highlights":"Share Buyback Upper Limit Amount: 2,000,000,000 yen (Unknown)\nShare Buyback Upper Limit Shares: 530,000 shares (Unknown)\nNumber of Shares Offered (Purchased by Underwriters): 1,153,600 shares (Unknown)\nOver-allotment Share Offering Upper Limit: 173,000 shares (Unknown)","jir_category":"","jir_hashtags":"#MochidaPharmaceuticalCoLtd, #CapitalPolicy, #ShareOffering, #ShareBuyback, #JapaneseStocks","jir_key_figures":"Share Buyback Upper Limit Amount: 2,000,000,000 yen\nShare Buyback Upper Limit Shares: 530,000 shares\nNumber of Shares Offered (Purchased by Underwriters): 1,153,600 shares\nOver-allotment Share Offering Upper Limit: 173,000 shares\nLock-up Period: 180 days from share offering price determination date","jir_meta_title":"Mochida Pharmaceutical Resolves Share Buyback with a 2 Billion Yen Cap and Share Offering of 1,153,600 Shares","jir_meta_description":"Mochida Pharmaceutical Co., Ltd. has decided to conduct a share buyback with an upper limit of 2,000,000,000 yen and 530,000 shares starting May 18, 2026, and a share offering of 1,153,600 shares through Mitsubishi UFJ Morgan Stanley Securities. The company aims to optimize shareholder composition and accelerate growth strategies.","jir_og_title":"Mochida Pharmaceutical Resolves Share Offering and Share Buyback","jir_og_description":"Mochida Pharmaceutical announces a share offering of 1,153,600 shares and a share buyback capped at 2 billion yen to accelerate its growth strategy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-37782","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n